{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:44:01Z","timestamp":1791420241308,"version":"4.3.3"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T00:00:00Z","timestamp":1481068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer Healthcare A.G."},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C552\/A17720"],"award-info":[{"award-number":["C552\/A17720"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.omto.2016.12.001","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T17:15:43Z","timestamp":1481822143000},"page":"55-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution"],"prefix":"10.1016","volume":"4","author":[{"given":"Irene","family":"Kuhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Bauzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Hermiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2016.12.001_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ygyno.2013.03.026","article-title":"An international assessment of ovarian cancer incidence and mortality","volume":"130","author":"Lowe","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2016.12.001_bib2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/14737159.2016.1188692","article-title":"Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer","volume":"16","author":"English","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.omto.2016.12.001_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.cgt.7700472","article-title":"A phase I\/II trial of rAd\/p53 (SCH 58500) gene replacement in recurrent ovarian cancer","volume":"9","author":"Buller","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2016.12.001_bib4","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1038\/sj.onc.1209037","article-title":"Oncolytic viral therapies\u2014the clinical experience","volume":"24","author":"Aghi","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.omto.2016.12.001_bib5","first-page":"1562","article-title":"Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3\u00a0weeks in patients with recurrent\/refractory epithelial ovarian cancer","volume":"20","author":"Vasey","year":"2002","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2016.12.001_bib6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ctrv.2010.12.003","article-title":"The emerging role of viruses in the treatment of solid tumours","volume":"37","author":"Bourke","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.omto.2016.12.001_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ygyno.2010.10.031","article-title":"Oncolytic virotherapy of gynecologic malignancies","volume":"120","author":"Hartkopf","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2016.12.001_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.omto.2016.12.001_bib9","first-page":"2391","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.omto.2016.12.001_bib10","doi-asserted-by":"crossref","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","article-title":"Directed evolution generates a novel oncolytic virus for the treatment of colon cancer","volume":"3","author":"Kuhn","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omto.2016.12.001_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1242\/dev.105.2.223","article-title":"Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane","volume":"105","author":"Barcellos-Hoff","year":"1989","journal-title":"Development"},{"key":"10.1016\/j.omto.2016.12.001_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1242\/jcs.99.2.407","article-title":"Cytodifferentiation of mouse mammary epithelial cells cultured on a reconstituted basement membrane reveals striking similarities to development in\u00a0vivo","volume":"99","author":"Aggeler","year":"1991","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omto.2016.12.001_bib13","doi-asserted-by":"crossref","first-page":"9064","DOI":"10.1073\/pnas.89.19.9064","article-title":"Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells","volume":"89","author":"Petersen","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2016.12.001_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-009-0502-2","article-title":"HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment","volume":"122","author":"Weigelt","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.omto.2016.12.001_bib15","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1038\/ncomms7220","article-title":"Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in\u00a0vivo efficacy","volume":"6","author":"Kenny","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2016.12.001_bib16","doi-asserted-by":"crossref","first-page":"015016","DOI":"10.1088\/1748-6041\/10\/1\/015016","article-title":"In\u00a0vivo bioengineered ovarian tumors based on collagen, matrigel, alginate and agarose hydrogels: a comparative study","volume":"10","author":"Zheng","year":"2015","journal-title":"Biomed. Mater."},{"key":"10.1016\/j.omto.2016.12.001_bib17","first-page":"781","article-title":"Inhibition of cell-proliferation by an adenovirus vector expressing the human wild type-p53 protein","volume":"3","author":"Bacchetti","year":"1993","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omto.2016.12.001_bib18","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3892\/ol.2016.4155","article-title":"20(S)-Protopanaxadiol saponins inhibit SKOV3 cell migration","volume":"11","author":"Li","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omto.2016.12.001_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/sj.gt.3302851","article-title":"High-performance liquid chromatography method for rapid assessment of viral particle number in crude adenoviral lysates of mixed serotype","volume":"14","author":"Kuhn","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2016.12.001_bib20","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1158\/0008-5472.CAN-09-0645","article-title":"Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses","volume":"69","author":"Strauss","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2016.12.001_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omto.2016.12.001_bib22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world\u2019s first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.omto.2016.12.001_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.gt.3301377","article-title":"Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?","volume":"8","author":"Kirn","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2016.12.001_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/rmv.1796","article-title":"Viruses exploit the function of epidermal growth factor receptor","volume":"24","author":"Zheng","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.omto.2016.12.001_bib25","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jgm.427","article-title":"Enhancing adenovirus-mediated gene transfer in\u00a0vitro and in\u00a0vivo by addition of protamine and hydrocortisone","volume":"5","author":"Lin","year":"2003","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omto.2016.12.001_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(03)01139-2","article-title":"Why did p53 gene therapy fail in ovarian cancer?","volume":"4","author":"Zeimet","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2016.12.001_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2013.08.032","article-title":"Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: implications for ovarian cancer therapy","volume":"447","author":"Thoma","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.omto.2016.12.001_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1525-0016(03)00200-4","article-title":"Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus","volume":"8","author":"Kanerva","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2016.12.001_bib29","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1128\/jvi.64.11.5510-5518.1990","article-title":"Transcription factors NFI\u00a0and NFIII\/oct-1 function independently, employing different mechanisms to enhance adenovirus DNA replication","volume":"64","author":"Mul","year":"1990","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2016.12.001_bib30","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1128\/JVI.78.4.1928-1935.2004","article-title":"Bending of adenovirus origin DNA by nuclear factor I as shown by scanning force microscopy is required for optimal DNA replication","volume":"78","author":"Mysiak","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2016.12.001_bib31","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2016.12.001_bib32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ygyno.2013.06.003","article-title":"A phase I clinical trial of Ad5\/3-\u039424, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer","volume":"130","author":"Kim","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2016.12.001_bib33","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2174\/138920112800958913","article-title":"Oncolytic viruses for induction of anti-tumor immunity","volume":"13","author":"Tong","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.omto.2016.12.001_bib34","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4161\/cbt.7.8.6216","article-title":"Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation","volume":"7","author":"Benencia","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.omto.2016.12.001_bib35","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.3390\/v7122953","article-title":"Dendritic cells in oncolytic virus-based anti-cancer therapy","volume":"7","author":"Kim","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.omto.2016.12.001_bib36","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1158\/1078-0432.CCR-10-2848","article-title":"Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?","volume":"17","author":"Naik","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2016.12.001_bib37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nm.3848","article-title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","volume":"21","author":"Ilkow","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2016.12.001_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2121-14-7","article-title":"Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Cell Biol."},{"key":"10.1016\/j.omto.2016.12.001_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2014.11.001","article-title":"Engineering of tumor microenvironments","volume":"79-80","author":"Hutmacher","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omto.2016.12.001_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.addr.2014.07.003","article-title":"Three-dimensional modeling of ovarian cancer","volume":"79-80","author":"White","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omto.2016.12.001_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/path.4663","article-title":"Genetically-defined ovarian cancer mouse models","volume":"238","author":"Morin","year":"2016","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.omto.2016.12.001_bib42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1101\/gr.118786.110","article-title":"Collaborative Cross mice and their power to map host susceptibility to Aspergillus fumigatus infection","volume":"21","author":"Durrant","year":"2011","journal-title":"Genome Res."},{"key":"10.1016\/j.omto.2016.12.001_bib43","series-title":"Adenovirus Methods and Protocols","first-page":"1","article-title":"Preparation and titration of cesium chloride banded adenovirus stock","author":"Tollefson","year":"1999"},{"key":"10.1016\/j.omto.2016.12.001_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1099\/0022-1317-11-2-95","article-title":"Isolation of temperature-sensitive mutants of adenovirus type 5","volume":"11","author":"Williams","year":"1971","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omto.2016.12.001_bib45","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1128\/jvi.21.3.1243-1246.1977","article-title":"Isolation of a variant of human adenovirus serotype 2 that multiplies efficiently on monkey cells","volume":"21","author":"Klessig","year":"1977","journal-title":"J.\u00a0Virol."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:18:10Z","timestamp":1762496290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770516300559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":45,"alternative-id":["S2372770516300559"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2016.12.001","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s).","name":"copyright","label":"Copyright"}]}}